Key result
Percutaneous LAA occlusion maintains a low residual ischemic stroke rate of ~1.5% per year.
Why the study?
Percutaneous left atrial appendage occlusion is a potential alternative to oral anticoagulation in patients with AF, and this study sought to determine the residual risk of ischemic stroke following the procedure.
Does percutaneous left atrial appendage occlusion prevent ischemic stroke in patients with atrial fibrillation?
Meta-Analysis (n=5,533)
Randomized trials included
Does percutaneous left atrial appendage occlusion prevent ischemic stroke in patients with atrial fibrillation?
Patients with atrial fibrillation undergoing percutaneous LAA occlusion experience a pooled residual ischemic stroke rate of 1.5% per year, which exceeds the 1% annual risk threshold for a class 2a guideline recommendation for oral anticoagulation.
Answers are grounded in this paper and cite their sources.
Residual stroke risk after LAA occlusion exceeds OAC thresholds; confirms need for adjunctive prevention strategies in AF.
Background: Guidelines recommend oral anticoagulation for stroke prevention in patients with atrial fibrillation (AF) and additional risk factors (class 1: risk ≥2% per year, class 2a: risk ≥1 but <2% per year). Percutaneous left atrial appendage (LAA) occlusion has been introduced as a potential alternative to oral anticoagulation. Research Question: What is the residual risk of ischemic stroke following percutaneous LAA occlusion? Methods: We performed a preregistered (CRD420251181525) systematic review of MEDLINE and Embase to May 18, 2026, to identify randomized trials of percutaneous LAA occlusion in patients with AF. We included trials with ≥100 participants assigned to percutaneous LAA occlusion and ≥6 months of follow-up. We excluded trials exclusively testing this treatment as a concomitant procedure or within ≤180 days of catheter ablation. We derived annualized event rates from individual trials and pooled them using random-effects meta-analysis in R. Results: From 6,034 citations, we identified nine eligible trials that included 5,533 participants randomized to percutaneous LAA occlusion. Five trials compared percutaneous LAA occlusion with oral anticoagulation (2,878 device recipients), one with single antiplatelet/no antithrombotic therapy (320 device recipients), and three compared occlusion devices head-to-head (2,335 device recipients). Three trials only included patients unsuitable for oral anticoagulation, and no trial studied percutaneous LAA occlusion in addition to oral anticoagulation. The mean age of study participants ranged from 69.4-78.5 years, 28.8%-42.4% were female and the mean CHA 2 DS 2 -VASc score ranged from 3.4-5.2. The proportion of patients with persistent/permanent AF ranged from 30.7%-73.6%, while prior stroke/transient ischemic attack ranged from 7.9%-40.5%. Eight trials including 5,297 device recipients reported on ischemic stroke following percutaneous LAA occlusion. During a weighted mean average follow-up of 3.4 years, the pooled annualized rate of ischemic stroke following percutaneous LAA occlusion was 1.5% (95% confidence interval [CI] 1.3%-1.7%) per year (I 2 =0%) (Figure). Event rates were similar in trials testing WATCHMAN 2.5 (1.5% per year), WATCHMAN FLX (1.6% per year) and Amplatzer Amulet (1.6% per year) (p=0.96). Rates of ischemic stroke were similar in trials that enrolled patients suitable (1.4%, 95% CI 1.1%-1.8%) and unsuitable for oral anticoagulation (1.6%, 95% CI 1.4%-1.9%) (p=0.34). Due to insufficient data, we were unable to perform prespecified subgroup analyses according to CHA 2 DS 2 -VASc score, AF pattern, and prior stroke. Conclusions: A sizeable proportion of percutaneous LAA occlusion recipients have a residual risk of stroke that exceeds the current threshold for a class 2a recommendation for oral anticoagulation. Published data were insufficient to identify higher-risk subgroups.
No takes yet. Share an insight, caveat, or question.
Benz et al. (2026) conducted a meta-analysis in Atrial fibrillation (n=5,533). Percutaneous left atrial appendage (LAA) occlusion (including WATCHMAN 2.5, WATCHMAN FLX, and Amplatzer Amulet) vs. Oral anticoagulation, single antiplatelet/no antithrombotic therapy, or head-to-head device comparison was evaluated on Annualized rate of ischemic stroke (1.5% per year, 95% CI 1.3%-1.7%). Percutaneous LAA occlusion in AF patients resulted in a pooled annualized residual ischemic stroke rate of 1.5% per year over a mean 3.4-year follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: